These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Silva R; Cachulo ML; Fonseca P; Bernardes R; Nunes S; Vilhena N; Faria de Abreu JR Ophthalmologica; 2011; 226(3):110-8. PubMed ID: 21822000 [TBL] [Abstract][Full Text] [Related]
24. Suicide and visual loss: a case report reflecting the need for recognition and management in ophthalmological settings. Johnson T; Rovner B; Haller J Semin Ophthalmol; 2014 Jul; 29(4):202-4. PubMed ID: 24702438 [TBL] [Abstract][Full Text] [Related]
25. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290 [TBL] [Abstract][Full Text] [Related]
26. Socio-economic deprivation and visual acuity at presentation in exudative age-related macular degeneration. Acharya N; Lois N; Townend J; Zaher S; Gallagher M; Gavin M Br J Ophthalmol; 2009 May; 93(5):627-9. PubMed ID: 19091850 [TBL] [Abstract][Full Text] [Related]
27. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Bandello F; Lafuma A; Berdeaux G Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):96-103. PubMed ID: 17197522 [TBL] [Abstract][Full Text] [Related]
28. Association between foveal microstructure and visual outcome in age-related macular degeneration. Shin HJ; Chung H; Kim HC Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888 [TBL] [Abstract][Full Text] [Related]
29. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
30. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Hopley C; Salkeld G; Mitchell P Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009 [TBL] [Abstract][Full Text] [Related]
31. Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care. Reznicek L; Muhr J; Ulbig M; Kampik A; Mayer WJ; Haritoglou C; Neubauer A; Wolf A Br J Ophthalmol; 2014 Oct; 98(10):1333-7. PubMed ID: 24903670 [TBL] [Abstract][Full Text] [Related]
32. Qualifying to Use a Home Monitoring Device for Detection of Neovascular Age-Related Macular Degeneration. Thomas M; Wolfson Y; Zayit-Soudry S; Bressler SB; Bressler NM JAMA Ophthalmol; 2015 Dec; 133(12):1425-30. PubMed ID: 26468999 [TBL] [Abstract][Full Text] [Related]
33. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine. Finger RP; Hoffmann AE; Fenwick EK; Wolf A; Kampik A; Kernt M; Neubauer AS; Hirneiss C Br J Ophthalmol; 2012 Jul; 96(7):997-1002. PubMed ID: 22535331 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes. Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166 [TBL] [Abstract][Full Text] [Related]
36. Burden of illness of neovascular age-related macular degeneration in Canada. Cruess A; Zlateva G; Xu X; Rochon S Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200 [TBL] [Abstract][Full Text] [Related]
37. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560 [TBL] [Abstract][Full Text] [Related]
38. Vision-related quality of life in patients suffering from age-related macular degeneration. Berdeaux GH; Nordmann JP; Colin E; Arnould B Am J Ophthalmol; 2005 Feb; 139(2):271-9. PubMed ID: 15733988 [TBL] [Abstract][Full Text] [Related]
39. SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES. Brown MM; Brown GC; Lieske HB; Tran I; Turpcu A; Colman S Retina; 2016 Feb; 36(2):285-98. PubMed ID: 26428606 [TBL] [Abstract][Full Text] [Related]
40. Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes. Ozkaya A; Alkin Z; Osmanbasoglu OA; Ozkaya HM; Demirok A J Fr Ophtalmol; 2014 Apr; 37(4):280-7. PubMed ID: 24657215 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]